Pioneer of global small-cap investing raises stake in THIS housing finance stock. Do you own?
Smallcap World Fund Inc. has increased its stake in Home First Finance Company India by nearly 3%, taking its total shareholding in the company to above 7%. On Thursday, Home First Finance Company share price gained nearly 2%. The small-cap stock rose as much as 2.05% to ₹ 1,175.80 apiece on the BSE.
Smallcap World Fund Inc. held 5,013,7001 equity shares of Home First Finance Company India as of 2 December 2024, aggregating to 5.6102% stake in the company.
On 30 April 2025, the fund acquired additional 3,023,818 Home First Finance shares, equivalent to 2.94% stake in the company, through the open market.
With the latest acquisition, Smallcap World Fund's shareholding in Home First Finance Company India has increased to 7.8078%, with 8,037,518 shares.
As per the latest shareholding pattern of Home First Finance Company India Ltd as of quarter ending March 2025, promoters held 1,28,35,183 shares in the company, aggregating to 12.47% stake, while public shareholders accounted for the remaining 87.53% of the holding.
Among the public shareholders, Foreign Portfolio Investors (FPI) held a 36.53% stake in Home First Finance Company India Ltd as on March 2025.
Home First Finance shares have delivered strong returns, gaining 18% over the past month and rising 12% year-to-date (YTD). The small-cap stock has increased 31% in the past year and has delivered a strong 50% return over the last three years.
At 11:45 AM, Home First Finance share price was trading 1.25% higher at ₹ 1,166.60 apiece on the BSE, commanding a market capitalisation of more than ₹ 12,035 crore.
Read all Stock Market news here
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
3 hours ago
- Mint
Biocon shares in focus after board opens up QIP fundraising on 16 June, sets floor price at ₹340.20/share
Biocon shares will be in focus of stock market investors after the company's board of directors announce the opening of the QIP (Qualified Institutional Placement) fundraising on 16 June 2025, according to an exchange filing. 'The Fund Raising Committee has at its meeting held today, i.e. Monday, June 16, 2025, authorizing the opening of the issue,' said Biocon in the BSE filing. The pharma company also approved the floor price of the QIP issue to be at ₹ 340.20 per equity share. Biocon disclosed that the company has the ability to discount the offer further to not more than 5 per cent on the floor price of the QIP issue. 'The company may, at its discretion, offer a discount of not more than 5% on the floor price for the issue,' said Biocon in the exchange filing. The firm will decide the issue price after consultation with the book-running lead managers appointed in relation to the case. Biocon shares closed 0.52 per cent higher at ₹ 357.30 after Monday's stock market session, compared to ₹ 355.45 at the previous stock market close. The company announced the outcome of its board meeting after the market operating hours on 16 June 2025. Shares of the pharmaceutical company have given investors more than 637.35 per cent since its listing in the Indian stock market in 2004. However, the shares lost 6.37 per cent in the last five years. In the last one-year period, the stock has gained 8.71 per cent, and is trading 4.31 per cent higher in the last five stock market sessions. Biocon shares hit their 52-week high level at ₹ 404.60 on 21 January 2025, and the 52-week low level was at ₹ 290.80 on 3 March 2025, according to data collected from the BSE website. The pharma company's market capitalisation (M-Cap) was at ₹ 42,897.44 crore as of the stock market close on Monday, 16 June 2025.
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Markets snap two-day losing streak, shrug off Israel-Iran conflict
Snapping their two-day losing streak, benchmark indices rose on Monday, driven by gains in banking and technology heavyweights, shrugging off the Iran-Israel conflict. Continued buying by domestic institutional investors (DIIs) also helped underpin gains. Most global markets also ended positive, stoking concerns that traders may be undermining the implications of West Asia tensions. The BSE Sensex closed the session at 81,796, up 678 points or 0.8 per cent, while the NSE Nifty rose to 24,947, gaining 228 points or 0.9 per cent. The total market capitalisation of BSE-listed firms increased by ₹3.3 trillion, reaching ₹451 trillion. DIIs were net buyers of equities worth ₹5,781 crore, while foreign institutional investors (FIIs) sold shares worth ₹2,539 crore. DIIs have been net buyers for 20 consecutive sessions, purchasing shares worth ₹94,500 crore. This marks the longest buying spree since the 29-day period of continuous buying that ended on March 19. HDFC Bank, which rose 0.9 per cent, was the biggest contributor to the Sensex, followed by Infosys, which gained 1.4 per cent. HDFC Bank's stocks rose after Jefferies named the private lender its top pick in a report, citing benefits from easing regulations, lower interest rates, and improved credit growth. The gains were partly attributed to a "buying the dip" strategy, as the stock had declined over 3 per cent the previous week. Despite ongoing attacks between Iran and Israel, crude oil prices stabilised as oil production facilities remained unaffected. The conflict has not yet led to the blockade of the Strait of Hormuz, which handles approximately one-fifth of the world's daily crude shipments. Brent crude was trading below $74, down 1.9 per cent. Gold prices declined by 0.5 per cent, trading at $3,413 per ounce. Analysts expect investors to continue their "buying the dip" approach as long as the conflict does not escalate further and other countries remain uninvolved. "Despite ongoing geopolitical tensions between Israel and Iran, the market moved higher, supported by gains in largecap stocks. Investors maintained their focus on long-term fundamentals amid volatile conditions. Geopolitical developments in West Asia are likely to influence near-term market sentiment, with any signs of de-escalation being closely monitored. Smallcap stocks are expected to underperform in the short term, given their elevated valuations and lack of short-term catalysts," said Vinod Nair, Head of Research at Geojit Financial Services. The market breadth was weak, with 2,151 stocks declining and 1,944 advancing. All but three Sensex stocks gained. Reliance Industries rose 0.76 per cent, and Bharti Airtel gained 1.04 per cent, contributing significantly to Sensex's gains. Tata Motors fell 3.8 per cent — most among Sensex and Nifty components -- after projecting financial year 2026 operating margins of 5 per cent-7 per cent for its luxury unit JLR, below its earlier target of 10 per cent. "The market's resilience amid lingering geopolitical tensions is encouraging. However, participants should remain cautious and not get carried away by a single-day rebound, especially as the index approaches the upper band of its current consolidation range, i.e., the 25,000–25,200 zone. We recommend maintaining a stock-specific trading approach, given the mixed trends across sectors, with a preference for relatively less volatile counters," said Ajit Mishra, SVP of Research at Religare Broking.
Mint
5 hours ago
- Mint
Biocon shares in focus after board opens up QIP fundraising on 16 June, sets floor price at ₹340.20/share
Biocon shares will be in focus of stock market investors after the company's board of directors announce the opening of the QIP (Qualified Institutional Placement) fundraising on 16 June 2025, according to an exchange filing. 'The Fund Raising Committee has at its meeting held today, i.e. Monday, June 16, 2025 authorizing the opening of the issue,' said Biocon in the BSE filing. Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
